Lisa Butterfield, Cancer Immunotherapy Consultant and Advisory Board Member, shared on LinkedIn:
“I’m both delighted and relieved that our collaborative work on circulating autoantibodies in melanoma patients from our cancer vaccine trial has now been published.
Congratulations to first author Paul M. and to Juraj Adamik, and our collaborators, including Aaron Ring. We identified autoantibodies to critical immune trafficking pathways, tumor antigens and a signature correlating with patient clinical outcomes and the patient’s cDC2 cells.
Thanks to Parker Institute and PICI UCSF for the support.”
Title: Autoantibodies associate with clinical outcome in patients with melanoma treated with a dendritic cell-based vaccine
Authors: Paul V. Munson, Juraj Adamik, Yile Dai,Marshall, A. Thompson, Christine N. Spencer, Caleigh Mandel-Brehm, Aaron M. Ring and Lisa H. Butterfield.
You can also read: ESMO 2026: What’s New in Melanoma Immunotherapy?
